Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

15.58
+0.0000
Post-market: 15.580.00000.00%17:54 EDT
Volume:1.08M
Turnover:16.70M
Market Cap:1.71B
PE:-9.96
High:15.68
Open:15.36
Low:15.25
Close:15.58
Loading ...

NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
17 Apr

Why NovoCure Stock Was Withering on Wednesday

Motley Fool
·
17 Apr

Novocure Is Maintained at Neutral by Wedbush

Dow Jones
·
16 Apr

Novocure Is Maintained at Neutral by JP Morgan

Dow Jones
·
10 Apr

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Zacks
·
10 Apr

NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week

Simply Wall St.
·
08 Apr

Press Release: Novocure to Report First Quarter 2025 Financial Results

Dow Jones
·
01 Apr

Novocure to Report First Quarter 2025 Financial Results

THOMSON REUTERS
·
01 Apr

Wells Fargo Sticks to Its Buy Rating for NovoCure (NVCR)

TIPRANKS
·
06 Mar

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Business Wire
·
04 Mar

Stock Track | NovoCure Plummets 5.3% as EPS Misses Expectations in Full-Year 2024 Results

Stock Track
·
28 Feb

NovoCure Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
28 Feb

NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...

GuruFocus.com
·
28 Feb

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
28 Feb

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

Benzinga
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: NovoCure (NVCR), Altimmune (ALT)

TIPRANKS
·
28 Feb

Novocure Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks
·
27 Feb

Stock Track | NovoCure Stock Plummets 8.38% in Pre-Market as Wider Q4 Loss Offsets Revenue Growth

Stock Track
·
27 Feb

Stock Track | NovoCure Plunges 6.4% in Pre-Market Trading as Q4 Loss Widens on Higher Expenses

Stock Track
·
27 Feb